MAIA Biotechnology, Inc. (MAIA) stock
MAIANYSEPharmaceutical PreparationsFiscal year ends December 31
$1.30+0.05 (+4.00%)
Close on Nov 18, 2026Market cap $79.07MP/E –Yield –
MAIA Biotechnology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MAIA Biotechnology's operating income for the twelve months ending Jun 30, 2026 was -$28.95M. For fiscal 2025 it was -$24.27M. The highest annual figure on record is -$7.79M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.27M | – |
| FY2024 | Dec 31, 2024 | -$16.96M | – |
| FY2023 | Dec 31, 2023 | -$20.18M | – |
| FY2022 | Dec 31, 2022 | -$16.18M | – |
| FY2021 | Dec 31, 2021 | -$7.79M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.32M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.43M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.96M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.66M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.23M | – |
See a number that looks wrong?